Arndt Vogel
@arndtvogel
Clinician-Scientist, ESMO Ambassador, focussed on Liver Cancer & Precision Oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
ID: 1211086357
23-02-2013 08:40:33
1,1K Tweet
7,7K Followers
578 Following
FLOT/TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎 PRODIGE 51-FFCD-GASTFOX phs 3 trial 👉ORR 62 vs 53% 👉mPFS 7·59 vs 5·98 mo 👉mOS 15·08 vs 12·65 mo 🧐Intersting option for fit pts
